Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

PHARMACEUTICALS

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

DABIGATRAN ETEXILATE IMPURITYC CRS (10 MG)

DABIGATRAN ETEXILATE IMPURITYC CRS (10 MG)

ND

DISCOVER
PIMOZIDE FOR SYSTEM SUITABILITY CRS (15 MG)

PIMOZIDE FOR SYSTEM SUITABILITY CRS (15 MG)

ND

DISCOVER
TRIMETHOPRIM FOR PEAK IDENTIFICATION CRS (1.001 MG)

TRIMETHOPRIM FOR PEAK IDENTIFICATION CRS (1.001 MG)

NA

DISCOVER
DABIGATRAN ETEXILATE MESILATECRS (110 MG)

DABIGATRAN ETEXILATE MESILATECRS (110 MG)

ND

DISCOVER
PIMOZIDE IMPURITY D CRS (0.01MG)

PIMOZIDE IMPURITY D CRS (0.01MG)

ND

DISCOVER
CHRYSANTHEMUM FLOWER FOR SYSTEM SUITABILITY HRS (520 MG)

CHRYSANTHEMUM FLOWER FOR SYSTEM SUITABILITY HRS (520 MG)

ND

DISCOVER
LONICERA JAPONICA FLOWER FOR PEAK IDENTIFICATION HRS (220 MG

LONICERA JAPONICA FLOWER FOR PEAK IDENTIFICATION HRS (220 MG

ND

DISCOVER
VASICINE CRS (15 MG)

VASICINE CRS (15 MG)

ND

DISCOVER
CABAZITAXEL ACETONE CRS (120 MG)

CABAZITAXEL ACETONE CRS (120 MG)

ND

DISCOVER
FLUOCORTOLONE  PIVALATE FOR PEAK IDENTIFICATION CRS (10 MG)

FLUOCORTOLONE PIVALATE FOR PEAK IDENTIFICATION CRS (10 MG)

ND

DISCOVER
LEVOCETIRIZINE FOR SYSTEM SUITABILITY CRS (0.2 MG)

LEVOCETIRIZINE FOR SYSTEM SUITABILITY CRS (0.2 MG)

ND

DISCOVER
LEVOCETIRIZINE DIHYDROCHLORIDE CRS (70 MG)

LEVOCETIRIZINE DIHYDROCHLORIDE CRS (70 MG)

ND

DISCOVER